Abstract

Abstract This clinical investigation examined the effect of a sanguinarine extract on bacterial plaque growth in man. Three different mouthrinses were examined: (i) Veadent® containing 0.03% sanguinarine and 0.2% zinc chloride (test rinse); (ii) a vehicle solution containing all the excipients of Veadent® except the 0.03% sanguinarine (control rinse); (iii) Hibident® a 0.2% chlorhexidine digluconate formulation (positive control rinse). The trial in which 12 dental students participated, was designed as a single-blind, cross-over study. During 3 experimental periods of 18 days, the participants refrained from mechanical oral hygiene and rinsed twice a day with one of the above mentioned solutions. Between experimental phases, a wash-out period of 11 days was instituted. In each subject, 4 teeth were randomly selected for assessment. Clinical evaluations were performed at days 1 (0, 4, 8, 12 hours), 2, 4, 11 and 18. The plaque on the buccal surfaces of the selected teeth was disclosed with neutral red 0.5% and colour slides taken. The % of the tooth surface covered with plaque was calculated planimetrically from these colour slides. The present results show an excellent anti-plaque effect with Hibident®, a very small effect with Veadent® and a negligible effect with the vehicle solution without the sanguinarine. These findings would suggest that the Veadent® mouthrinse would have at most only a limited role as a plaque inhibitor.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.